Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
|Videos|June 8, 2017
Novel Prostate Cancer Risk Classifier Highly Prognostic for Metastases
Author(s)Daniel Eidelberg Spratt, MD
This video highlights a clinical-genomic risk classification system that is highly prognostic for distant metastasis and more accurate than clinical risk assessments.
Advertisement
In this video, Daniel Eidelberg Spratt, MD, of the University of Michigan, discusses how the use of a readily available genomic classifier combined with clinicopathologic variables can generate a simple to use clinical-genomic risk classification system that is highly prognostic for distant metastasis and more accurate than clinical risk assessments.
Spratt presented results of the study (
Advertisement
Related to this article
Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.
Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Parul N. Barry, MD, FACRO, discussed extending advanced radiation services to satellite sites and offered guidance for early-career physicians building new programs.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
2
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
3
Setting Up an HDR Brachytherapy Program Amid a National Decline
4
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
5